Radioimmunotherapy and Gemcitabine Combination Shows Early Promise for Metastatic Pancreatic Ductal Cancer

NEW ORLEANS — A combination of several small doses of an investigational radioimmunotherapy and the chemotherapy gemcitabine had superior outcomes compared with radioimmunotherapy alone in patients with metastatic pancreatic ductal cancer, according to phase Ib clinical trial data presented at the AACR special conference on Pancreatic Cancer: Innovations in Research and Treatment, held May 18-21.

“Radiation therapy is an effective therapy against most cancers, including pancreatic cancer,” said Vincent J. Picozzi Jr., M.D., director of the Pancreas Center of Excellence at the Virginia Mason Medical Center’s Digestive Disease Institute. “However, an antibody that can recognize a target found only on most pancreatic cancer cells and that can carry a radioactive source with it has the potential to kill cancer cells throughout the body, as opposed to conventional radiation therapy, which is delivered as a ‘beam’ to a specific area of the body.”

One such radioimmunotherapy, $^{90}$Y-clivatuzumab tetraxetan, was used in this trial: PAM4 is the antibody and yttrium-90 ($^{90}$Y) is the source of radiotherapy, and they are held together by a linker.

“The antibody binds to a protein called MUC5ac, which is a protein found on the surface of most pancreatic cancer cells, but not normal cells,” explained Picozzi. $^{90}$Y, a radioactive form of yttrium that emits radiation over a distance of about a quarter of an inch, is attached to this antibody.

“We found that $^{90}$Y-clivatuzumab tetraxetan, when used with low-dose gemcitabine, is a safe, low-side-effect therapy that can prolong survival for at least some patients with metastatic pancreatic cancer, even when no chemotherapy options exist,” he added. “Our studies imply that radiolabelled antibodies are safe to use in advanced pancreatic cancer, and that it may be possible to attach other anticancer agents besides $^{90}$Y to clivatuzumab tetraxetan to fight pancreatic cancer.”

In this trial, 58 patients, median age 63.5 years, including 33 males, who received at least two prior therapies, were randomly assigned to either arm A (29 patients) or arm B (29 patients). Patients from both arms received 6.5 mCi/m$^2$ $^{90}$Y-clivatuzumab tetraxetan for three weeks, divided into multiple smaller doses per cycle. Patients from arm A also received low-dose...
Radioimmunotherapy and Gemcitabine Combination Shows Early Promise for Metastatic Pancreatic Ductal Cancer

Page 2 of 4

gemcitabine for one week and then in combination with the radioimmunotherapy for three weeks in each cycle. Patients received treatment for up to nine cycles, with four-week delays in between. The goal was to determine the safety and efficacy of this approach in this advanced population and evaluate the contribution of low-radiosensitizing doses of gemcitabine to the regimen.

Twenty-seven and 26 patients from arms A and B, respectively, completed at least one cycle of treatment. Patients terminated treatment due to disease progression or clinical deterioration, but 12 and 11 patients from arms A and B, respectively, completed two or more cycles of treatment.

The investigators found that the patients from arm A were 45 percent more likely to live longer, compared with patients from arm B. For patients who received only one treatment cycle, there was little survival difference between arm A and arm B. However, the overall survival was 7.9 months and 3.4 months, respectively, for patients from arm A and arm B who received multiple cycles of treatment.

In arm A, two patients had partial responses, and three patients are still alive 13 and 15 months after the start of their treatment.

Side effects were minimal, and the only clinically significant side effect that occurred with any frequency was reduction in blood counts, said Picozzi.

A larger, randomized phase III trial is underway to confirm these results.

“Patients are experiencing gradually increasing success in treating pancreatic cancer, even in advanced disease,” said Picozzi. “There are a variety of new approaches being developed for the treatment of pancreatic cancer, among the most promising of which is using the immune system in various ways to fight it.”

This study was funded by Immunomedics Inc. Picozzi declares no conflicts of interest.

###

Follow Pancreatic Cancer: Innovations in Research and Treatment on Twitter: #AACRPanCa14

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for
Radioimmunotherapy and Gemcitabine Combination Shows Early Promise for Metastatic Pancreatic Ductal Cancer

Page 3 of 4

cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.

Abstract

Presenter: Vincent J. Picozzi Jr., M.D.

Title: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least 2 prior therapies

Authors: Vincent J. Picozzi1, Ramesh K. Ramanathan2, Maeve A. Lowery3, Allyson J. Ocean4, Edith P. Mitchell5, Bert H. O'Neil6, Michael J. Guarino7, Paul R. Conkling8, Steven J. Cohen9, Nathan Bahary10, Richard C. Frank11, Tomislav Dragovich12, Benjamin B. Bridges13, Marie Lee14, Ronald L. Korn15, Neeta Pandit-Taskar16, Stanley J. Goldsmith17, Charles M. Intenzo18, Arif Sheikh19, Timothy C. Manzone7, Michael L. Miller8, Michael Yu9, Judith M. Joyce10, Edward B. Strauss11, Susan Passalaqua12, Ronald V. Dorn, III13, Michael J. Anderson8, Michael Holt15, Fadi S. Braith15, Fa-Chyi Lee16, Thomas E. Gribbin17, Donald A. Richards18, Alexander N. Starodub15, Wegener A. William19, Eileen M. O’Reilly3, Daniel D. Von Hoff2, David M. Goldenberg19. 1Virginia Mason Cancer Center, Seattle, WA, 2Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ, 3Memorial Sloan-Kettering Cancer Center, New York, NY, 4Weill Cornell Medical College, New York, NY, 5Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, 6UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 7Helen F. Graham Cancer Center at Christiana Care Health System, Newark, DE, 8US Oncology Phase II Group, Virginia Oncology Associates, Norfolk, VA, 9Fox Chase Cancer Center, Philadelphia, PA, 10University of Pittsburgh Medical Center, Pittsburgh, PA, 11Whittingham Cancer Center at Norwalk Hospital, Norwalk, CT, 12Banner MD Anderson Cancer Center, Gilbert, AZ, 13Luke’s Mountain States Tumor Institute, Meridian, ID, 14Virginia Mason Medical Center, Seattle, WA, 15Indiana University Health Center for Cancer Care, Goshen, IN, 16University of New Mexico Health Science Center, Albuquerque, NM, 17Lacks Cancer Center, Saint Mary's Health Care, Grand Rapids, MI, 18Tyler Cancer Center, US Oncology Research, McKesson Specialty Health, Houston, TX, 19Immunomedics, Inc., Morris Plains, NJ.

Background: Prior clinical studies in the first and second line setting showed radioimmunotherapy (RAIT) is a promising therapy for pancreatic cancer that avoids the side effects of further chemotherapy. This multicenter study evaluated the contribution of low radiosensitizing doses of gemcitabine (GEM) to fractionated doses of 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic ductal cancer after having received at least 2 prior systemic therapies.
Methods: Fifty-eight patients (33 males, 25 females; median age 63.5 years), 1.6 median years from diagnosis and with a median of 3 (2-7) prior treatments, were randomized to Arm A (N=29, 4-week cycles: 200 mg/m\(^2\) GEM, weekly, combined with 6.5 mCi/m\(^2\) \(^{90}\)Y-clivatuzumab tetraxetan, weekly the last 3 weeks) or Arm B (N=29, 3-week cycles: 6.5 mCi/m\(^2\) \(^{90}\)Y-clivatuzumab tetraxetan alone, once-weekly), repeating cycles after 4-week delays. Safety and efficacy were evaluated.

Results: None of the patients had infusion reactions, and as expected, cytopenias (predominantly thrombocytopenia) were the only significant toxicities, but mostly transient and manageable with infrequent hematologic support and little evidence of increased infection or bleeding. Patients terminated treatment cycles due to disease progression or clinical deterioration, not treatment toxicity. Fifty-three patients (27 Arm A, 26 Arm B, 91% overall) completed ≥1 full treatment cycle and thus were evaluable for efficacy, with 23 (12 Arm A, 11 Arm B; 40%) receiving multiple cycles, including 7 (6 Arm A, 1 Arm B; 12%) given 3-7 cycles. Two patients in Arm A had PRs by RECIST criteria. Karnofsky performance status (90-100 v 70-80), number of prior therapies, and tumor burden estimates (summed length of index lesions, serum CA 19-9 levels) correlated with overall survival (OS), but appear balanced between arms. Kaplan-Meier median OS was 3.9 months (1.0-16.7) in Arm A v 2.8 months (0.9-9.4) in Arm B (hazard ratio 0.54, 95% CI: 0.27-0.87; P=0.020, log-rank). The median OS for Arm A v Arm B increased to 7.9 v 3.4 months with multiple cycles (P= 0.004) and 3 patients in Arm A still being observed (11 – 17 months).

Conclusions: This randomized trial demonstrated the feasibility of performing clinical studies in metastatic pancreatic cancer patients after having at least 2 prior therapies (3rd line and beyond). With significant survival advantage and favorable safety profile, fractionated RAIT with \(^{90}\)Y-clivatuzumab tetraxetan and low-dose GEM appears promising in this difficult population, supporting Phase 3 studies of this combination now being initiated.